Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison

Paul G. Richardson, Jae Hoon Lee, MD PhD, Istvan Majer, Arun Krishna, Richard C. Woodman, MD

Blood (2014) 124 (21): 2638.

https://doi.org/10.1182/blood.V124.21.2638.2638

Published: 2014

Journal Articles

MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up

Mridul Agrawal, Benjamin Hanfstein, MD, Philipp Erben, MD, Dominik Wolf, MD, Thomas Ernst, Susanne Saussele, MD, Alice Fabarius, PhD, Das Purkayasatha, Richard C. Woodman, MD, Rüdiger Hehlmann, MD, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2013) 122 (21): 1494.

https://doi.org/10.1182/blood.V122.21.1494.1494

Published: 2013

Journal Articles

Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, MD, Armin Leitner, MD, John Reynolds, Richard C. Woodman, MD, Laura Robin, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2010) 116 (21): 2283.

https://doi.org/10.1182/blood.V116.21.2283.2283

Published: 2010

Journal Articles

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Jennifer L Beaumont, MS*, John Coombs, PharmD, MBA*, amsi Bollu, V, PhD, MBA*, Richard C. Woodman, MD, David Cella, PhD*

Blood (2010) 116 (21): 3826.

https://doi.org/10.1182/blood.V116.21.3826.3826

Published: 2010

Journal Articles

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Susan Branford, PhD, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, PhD, Yu Jin, Richard C. Woodman, MD, Fabrizio Pane, MD, Dong-Wook Kim, Jerald P. Radich, MD, Timothy P. Hughes

Blood (2010) 116 (21): 889.

https://doi.org/10.1182/blood.V116.21.889.889

Published: 2010

Journal Articles

Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Ophelia Yin, PhD, FCP, Yen Lin Chia, PhD, Philipp D. le Coutre, MD, Richard C. Woodman, MD, Oliver G. Ottmann, MD, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 890.

https://doi.org/10.1182/blood.V116.21.890.890

Published: 2010

Journal Articles

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Jerald P. Radich, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Enrico Gottardi, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Lan Beppu, Yaping Shou, MD, PhD, Ariful Haque, MS, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 1130.

https://doi.org/10.1182/blood.V114.22.1130.1130

Published: 2009

Journal Articles

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, Hannah Daikeler, MD, Juliana Popa, MD, Thomas Schenk, MD, Armin Leitner, MD, Richard C. Woodman, MD, Andreas Hochhaus, MD, Martin C Müller, MD

Blood (2009) 114 (22): 2615.

https://doi.org/10.1182/blood.V114.22.2615.2615

Published: 2009

Journal Articles

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Simona Soverini, PhD, Enrico Gottardi, Lan Beppu, Martin C Müller, MD, Ariful Haque, MS, Yaping Shou, MD, PhD, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Giovanni Martinelli, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD

Blood (2009) 114 (22): 3292.

https://doi.org/10.1182/blood.V114.22.3292.3292

Published: 2009

Journal Articles

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Jim Wang, PhD, Richard C. Woodman, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 3298.

https://doi.org/10.1182/blood.V114.22.3298.3298

Published: 2009

Journal Articles

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.

Pierre Laneuville, MD, FRCPC, Clifford DiLea, PharmD, Jürgen Mestan, Ophelia Yin, PhD, FCP, Richard C. Woodman, MD, Paul Manley, PhD

Blood (2009) 114 (22): 510.

https://doi.org/10.1182/blood.V114.22.510.510

Published: 2009

Journal Articles

Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program

Alan S. Wayne, MD, Carla Renata Macedo, MD, Tomasz Szczudlo, MD, Richard C. Woodman, MD

Blood (2008) 112 (11): 4264.

https://doi.org/10.1182/blood.V112.11.4264.4264

Published: 2008

Journal Articles

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Philipp D. le Coutre, MD, Michael O’Dwyer, MD, FRCPI, FRCPath, Tomasz Szczudlo, MD, Richard C. Woodman, MD, Francis J. Giles, MD

Blood (2008) 112 (11): 4271.

https://doi.org/10.1182/blood.V112.11.4271.4271

Published: 2008

Journal Articles

Evaluation of the Impact of Myelosuppression on Treatment Response and Health-Related Quality of Life (HRQoL) in Patients with Chronic Myeloid Leukemia (CML).

K. Rosa, PhD, B. Crawford, MD, MPH, B. Syat, MPH, W. Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4584.

https://doi.org/10.1182/blood.V110.11.4584.4584

Published: 2007

Journal Articles

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Jennifer Stephens, Kim Carpiuc, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4586.

https://doi.org/10.1182/blood.V110.11.4586.4586

Published: 2007

Journal Articles

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Kim Carpiuc, Khalid El Ouagari, PhD, Jennifer Stephens, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4587.

https://doi.org/10.1182/blood.V110.11.4587.4587

Published: 2007

Journal Articles

Maintenance Dosing with Epoetin alfa Every Three Weeks (Q3W) in Anemic Patients with Cancer Receiving Chemotherapy Every Three Weeks: Final Results.

Vernon P. Montoya, MD, John Xie, PhD, Richard C. Woodman, MD

Blood (2005) 106 (11): 3555.

https://doi.org/10.1182/blood.V106.11.3555.3555

Published: 2005

NARROW

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison

MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up

Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.

Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Evaluation of the Impact of Myelosuppression on Treatment Response and Health-Related Quality of Life (HRQoL) in Patients with Chronic Myeloid Leukemia (CML).

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Maintenance Dosing with Epoetin alfa Every Three Weeks (Q3W) in Anemic Patients with Cancer Receiving Chemotherapy Every Three Weeks: Final Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only